COVID-19 State of emergency renewed for the urban agglomeration of Montréal
MONTRÉAL, April 8, 2022 /CNW Telbec/ - In accordance with the Civil Protection Act, Montréal's executive committee has renewed the state of emergency for the urban agglomeration of Montréal on April 8, for a period of five days.
The local state of emergency, which was declared on December 21, 2021, grants exceptional powers to the urban agglomeration, enabling it to respond to the current pandemic across its territory. In particular, it gives the urban agglomeration the power to mobilize the necessary resources and workforce to fight COVID-19.
The urban agglomeration of Montréal continues to collaborate closely with its team of experts from its emergency response coordination centre, the regional public health department and the healthcare and social services network, in order to fight the spread of COVID-19.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company"). This action, captioned Hope v. agilon health, inc., et...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...
